These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29928258)

  • 1. Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.
    Laurino A; Landucci E; Raimondi L
    Front Endocrinol (Lausanne); 2018; 9():290. PubMed ID: 29928258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3-iodothyronamine (T1AM) and the 3-iodothyroacetic acid (TA1) indicate a novel connection with the histamine system for neuroprotection.
    Laurino A; Gencarelli M; Raimondi L
    Eur J Pharmacol; 2021 Dec; 912():174606. PubMed ID: 34717926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism.
    Lehmphul I; Hoefig CS; Köhrle J
    Mol Cell Endocrinol; 2018 Jan; 460():219-228. PubMed ID: 28754352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution and cardiac metabolism of 3-iodothyronamine.
    Saba A; Chiellini G; Frascarelli S; Marchini M; Ghelardoni S; Raffaelli A; Tonacchera M; Vitti P; Scanlan TS; Zucchi R
    Endocrinology; 2010 Oct; 151(10):5063-73. PubMed ID: 20739399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox Properties of 3-Iodothyronamine (T1AM) and 3-Iodothyroacetic Acid (TA1).
    Gencarelli M; Lodovici M; Bellusci L; Raimondi L; Laurino A
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In the brain of mice, 3-iodothyronamine (T1AM) is converted into 3-iodothyroacetic acid (TA1) and it is included within the signaling network connecting thyroid hormone metabolites with histamine.
    Laurino A; De Siena G; Saba A; Chiellini G; Landucci E; Zucchi R; Raimondi L
    Eur J Pharmacol; 2015 Aug; 761():130-4. PubMed ID: 25941083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(3-Ethoxy-phenyl)-4-pyrrolidin-1-yl-3-trifluoromethyl-benzamide (EPPTB) prevents 3-iodothyronamine (T1AM)-induced neuroprotection against kainic acid toxicity.
    Landucci E; Gencarelli M; Mazzantini C; Laurino A; Pellegrini-Giampietro DE; Raimondi L
    Neurochem Int; 2019 Oct; 129():104460. PubMed ID: 31075293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on 3-iodothyronamine and its neurological and metabolic actions.
    Zucchi R; Accorroni A; Chiellini G
    Front Physiol; 2014; 5():402. PubMed ID: 25360120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-iodothyronamine (T1AM), a novel antagonist of muscarinic receptors.
    Laurino A; Matucci R; Vistoli G; Raimondi L
    Eur J Pharmacol; 2016 Dec; 793():35-42. PubMed ID: 27815171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of scopolamine pretreatment on 3-iodothyronamine (T1AM) effects on memory and pain in mice.
    Laurino A; Lucenteforte E; De Siena G; Raimondi L
    Horm Behav; 2017 Aug; 94():93-96. PubMed ID: 28711308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Trace Amine-Associated Receptor 1 Agonist 3-Iodothyronamine Induces Biased Signaling at the Serotonin 1b Receptor.
    Bräunig J; Dinter J; Höfig CS; Paisdzior S; Szczepek M; Scheerer P; Rosowski M; Mittag J; Kleinau G; Biebermann H
    Front Pharmacol; 2018; 9():222. PubMed ID: 29593543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway.
    Rogowski M; Bellusci L; Sabatini M; Rapposelli S; Rahman SM; Chiellini G; Assadi-Porter FM
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5.
    Dinter J; Mühlhaus J; Wienchol CL; Yi CX; Nürnberg D; Morin S; Grüters A; Köhrle J; Schöneberg T; Tschöp M; Krude H; Kleinau G; Biebermann H
    PLoS One; 2015; 10(2):e0117774. PubMed ID: 25706283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.
    Bellusci L; Laurino A; Sabatini M; Sestito S; Lenzi P; Raimondi L; Rapposelli S; Biagioni F; Fornai F; Salvetti A; Rossi L; Zucchi R; Chiellini G
    Front Pharmacol; 2017; 8():905. PubMed ID: 29311919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.
    Dinter J; Mühlhaus J; Jacobi SF; Wienchol CL; Cöster M; Meister J; Hoefig CS; Müller A; Köhrle J; Grüters A; Krude H; Mittag J; Schöneberg T; Kleinau G; Biebermann H
    J Mol Endocrinol; 2015 Jun; 54(3):205-16. PubMed ID: 25878061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionary Conservation of 3-Iodothyronamine as an Agonist at the Trace Amine-Associated Receptor 1.
    Cöster M; Biebermann H; Schöneberg T; Stäubert C
    Eur Thyroid J; 2015 Sep; 4(Suppl 1):9-20. PubMed ID: 26601069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of 3-iodothyronamine (3-T
    Li ZM; Miller M; Gachkar S; Mittag J; Schriever SC; Pfluger PT; Schramm KW; De Angelis M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Feb; 1165():122553. PubMed ID: 33503577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyronamines and Analogues - The Route from Rediscovery to Translational Research on Thyronergic Amines.
    Chiellini G; Bellusci L; Sabatini M; Zucchi R
    Mol Cell Endocrinol; 2017 Dec; 458():149-155. PubMed ID: 28069535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous 3-Iodothyronamine (T
    Bandini L; Sacripanti G; Borsò M; Tartaria M; Fogliaro MP; Giannini G; Carnicelli V; Figuccia ME; Verlotta S; De Antoni F; Zucchi R; Ghelardoni S
    Life (Basel); 2022 Aug; 12(9):. PubMed ID: 36143389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Iodothyronamine, a Novel Endogenous Modulator of Transient Receptor Potential Melastatin 8?
    Khajavi N; Mergler S; Biebermann H
    Front Endocrinol (Lausanne); 2017; 8():198. PubMed ID: 28861042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.